Glenmark Pharmaceuticals gets final nod for Fluticasone Propionate Nasal Spray
Fluticasone Propionate Nasal Spray USP, 50 mcg per spray will be distributed in the U.S. by Glenmark Therapeutics Inc., USA
Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (USFDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Glenmark’s Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC) has been determined by the FDA to be bioequivalent to the reference listed drug, Flonase Allergy Relief Nasal Spray, 50 mcg per spray, of Haleon US Holding LLC and will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
